[1]
|
Maron, B.J., Desai, M.Y., Nishimura, R.A., et al. (2022) Management of Hypertrophic Cardiomyopathy: JACC State-of-the-Art Review. Journal of the American College of Cardiology, 79, 390-414.
https://doi.org/10.1016/j.jacc.2021.11.021
|
[2]
|
Batzner, A. and Seggewiß, H. (2020) Hypertrophe Kardiomyopa-thie [Hypertrophic Cardiomyopathy]. Herz, 45, 233-242.
https://doi.org/10.1007/s00059-020-04899-y
|
[3]
|
Semsarian, C., Ingles, J., Maron, M.S., et al. (2015) New Per-spectives on the Prevalence of Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 65, 1249-1254. https://doi.org/10.1016/j.jacc.2015.01.019
|
[4]
|
Younger, J., Lo, A., McCormack, L., et al. (2020) Hy-pertrophic Cardiomyopathy: Challenging the Status Quo? Heart, Lung and Circulation, 29, 556-565. https://doi.org/10.1016/j.hlc.2019.12.005
|
[5]
|
Butters, A., Semsarian, C.R., Bagnall, R.D., et al. (2021) Clinical Profile and Health Disparities in a Multiethnic Cohort of Patients with Hypertrophic Cardiomyopathy. Circulation: Heart Failure, 14, e007537.
https://doi.org/10.1161/CIRCHEARTFAILURE.120.007537
|
[6]
|
Geske, J.B., Ong, K.C., Siontis, K.C., et al. (2017) Women with Hypertrophic Cardiomyopathy Have Worse Survival. European Heart Journal, 38, 3434-3440. https://doi.org/10.1093/eurheartj/ehx527
|
[7]
|
Teekakirikul, P., Padera, R.F., Seidman, J.G. and Seidman, C.E. (2012) Hypertrophic Cardiomyopathy: Translating Cellular Cross Talk into Therapeutics. Journal of Cell Biology, 199, 417-421. https://doi.org/10.1083/jcb.201207033
|
[8]
|
Teekakirikul, P., Zhu, W., Huang, H.C. and Fung, E. (2019) Hypertrophic Cardiomyopathy: An Overview of Genetics and Management. Biomolecules, 9, Article No. 878. https://doi.org/10.3390/biom9120878
|
[9]
|
Goldspink, P.H., Warren, C.M., Kitajewski, J., Wolska, B.M. and So-laro, R.J. (2021) A Perspective on Personalized Therapies in Hypertrophic Cardiomyopathy. Journal of Cardiovascular Pharmacology, 77, 317-322.
https://doi.org/10.1097/FJC.0000000000000968
|
[10]
|
Ito, K., Patel, P.N., Gorham, J.M., et al. (2017) Identification of Pathogenic Gene Mutations in LMNA and MYBPC3 That Alter RNA Splicing. Proceedings of the National Academy of Sciences of the United States of America, 114, 7689-7694.
https://doi.org/10.1073/pnas.1707741114
|
[11]
|
Coppini, R., Ferrantini, C., Mugelli, A., Poggesi, C. and Cerbai, E. (2018) Altered Ca2+ and Na+ Homeostasis in Human Hypertrophic Cardiomyopathy: Implications for Arrhythmogenesis. Frontiers in Physiology, 9, Article 1391.
https://doi.org/10.3389/fphys.2018.01391
|
[12]
|
Marian, A.J. and Braunwald, E. (2017) Hypertrophic Cardiomyo-pathy: Genetics, Pathogenesis, Clinical Manifestations, Diagnosis, and Therapy. Circulation Research, 121, 749-770.
https://doi.org/10.1161/CIRCRESAHA.117.311059
|
[13]
|
Sabater-Molina, M., Pérez-Sánchez, I., Hernández del Rincón, J.P. and Gimeno, J.R. (2017) Genetics of Hypertrophic Cardiomyopathy: A Review of Current State. Clinical Genetics, 93, 3-14. https://doi.org/10.1111/cge.13027
|
[14]
|
Walsh, R., Thomson, K.L., Ware, J.S., et al. (2017) Re-assessment of Mendelian Gene Pathogenicity Using 7,855 Cardiomyopathy Cases and 60,706 Reference Samples. Ge-netics in Medicine, 19, 192-203.
https://doi.org/10.1038/gim.2016.90
|
[15]
|
Wooten, E.C., Hebl, V.B., Wolf, M.J., et al. (2013) Formin Homology 2 Domain Containing 3 Variants Associated with Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Genetics, 6, 10-18.
https://doi.org/10.1161/CIRCGENETICS.112.965277
|
[16]
|
Ochoa, J.P., Sabater-Molina, M., García-Pinilla, J.M., et al. (2018) Formin Homology 2 Domain Containing 3 (FHOD3) Is a Genetic Basis for Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology, 72, 2457-2467.
https://doi.org/10.1016/j.jacc.2018.10.001
|
[17]
|
Angelopoulos, A., Oikonomou, E., Vogiatzi, G., et al. (2021) Mi-croRNAs as Biomarkers in Hypertrophic Cardiomyopathy: Current State of the Art. Current Medicinal Chemistry, 28, 7400-7412.
https://doi.org/10.2174/0929867328666210405122703
|
[18]
|
Lioncino, M., Monda, E., Verrillo, F., et al. (2022) Hypertrophic Cardiomyopathy in RASopathies: Diagnosis, Clinical Characteristics, Prognostic Implications, and Man-agement. Heart Failure Clinics, 18, 19-29.
https://doi.org/10.1016/j.hfc.2021.07.004
|
[19]
|
邹玉宝, 宋雷. 中国成人肥厚型心肌病诊断与治疗指南解读[J]. 中国循环杂志, 2018, 33(S2): 68-73.
|
[20]
|
Veselka, J., Anavekar, N.S. and Charron, P. (2017) Hypertrophic Obstruc-tive Cardiomyopathy. Lancet, 389, 1253- 1267. https://doi.org/10.1016/S0140-6736(16)31321-6
|
[21]
|
Chrispin, J. and Marine, J.E. (2021) Atrial Fibrillation and Hypertrophic Cardiomyopathy: More Progress Needed. Journal of Car-diovascular Electrophysiology, 32, 667-668. https://doi.org/10.1111/jce.14874
|
[22]
|
Finocchiaro, G., Sheikh, N., Biagini, E., et al. (2020) The Electrocardiogram in the Diagnosis and Management of Patients with Hypertrophic Cardi-omyopathy. Heart Rhythm, 17, 142-151. https://doi.org/10.1016/j.hrthm.2019.07.019
|
[23]
|
Medical Masterclass Contributors and Firth, J. (2019) Cardiology: Hypertrophic Cardiomyopathy. Clinical Medicine Journal, 19, 61-63. https://doi.org/10.7861/clinmedicine.19-1-61
|
[24]
|
Makavos, G., Κairis, C., Tselegkidi, M.-E., et al. (2019) Hyper-trophic Cardiomyopathy: An Updated Review on Diagnosis, Prognosis, and Treatment. Heart Failure Reviews, 24, 439-459. https://doi.org/10.1007/s10741-019-09775-4
|
[25]
|
Maron, M.S., Rowin, E.J., Lin, D., et al. (2012) Prev-alence and Clinical Profile of Myocardial Crypts in Hypertrophic Cardiomyopathy. Circulation: Cardiovascular Imaging, 5, 441-447.
https://doi.org/10.1161/CIRCIMAGING.112.972760
|
[26]
|
Rudolph, A., Abdel-Aty, H., Bohl, S., et al. (2009) Noninvasive Detection of Fibrosis Applying Contrast-Enhanced Cardiac Magnetic Resonance in Different Forms of Left Ventricular Hypertrophy Relation to Remodeling. Journal of the American College of Cardiology, 53, 284-291. https://doi.org/10.1016/j.jacc.2008.08.064
|
[27]
|
葛均波, 徐永健, 王辰. 内科学[M]. 第9版. 北京: 人民卫生出版社, 2018: 265.
|
[28]
|
Ommen, S.R., Mital, S., Burke, M.A., et al. (2020) 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology/ American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 142, e533-e557.
https://doi.org/10.1161/CIR.0000000000000945
|
[29]
|
Nishimura, R.A., Seggewiss, H. and Schaff, H.V. (2017) Hypertrophic Obstructive Cardiomyopathy: Surgical Myectomy and Septal Ablation. Circulation Research, 121, 771-783. https://doi.org/10.1161/CIRCRESAHA.116.309348
|
[30]
|
Elliott, P.M., Anastasakis, A., Borger, M.A., et al. (2014) 2014 ESC Guidelines on Diagnosis and Management of Hypertrophic Cardiomyopathy: The Task Force for the Diagno-sis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). European Heart Journal, 35, 2733-2779.
https://doi.org/10.1093/eurheartj/ehu284
|
[31]
|
Prondzynski, M., Mearini, G. and Carrier, L. (2019) Gene Therapy Strategies in the Treatment of Hypertrophic Cardiomyopathy. Pflügers Archiv-European Journal of Physiology, 471, 807-815.
https://doi.org/10.1007/s00424-018-2173-5
|
[32]
|
Gedicke-Hornung, C., Behrens-Gawlik, V., Reischmann, S., et al. (2013) Rescue of Cardiomyopathy through U7snRNA- Mediated Exon Skipping in Mybpc3-Targeted Knock-in Mice. EMBO Molecular Medicine, 5, 1128-1145.
https://doi.org/10.1002/emmm.201202168
|
[33]
|
Trochet, D., Prudhon, B., Beuvin, M., et al. (2018) Allele-Specific Silencing Therapy for Dynamin 2-Related Dominant Centronuclear Myopathy. EMBO Molecular Medicine, 10, 239-253. https://doi.org/10.15252/emmm.201707988
|
[34]
|
Song, L., Su, M., Wang, S., et al. (2014) MiR-451 Is Decreased in Hypertrophic Cardiomyopathy and Regulates Autophagy by Targeting TSC1. Journal of Cellular and Molecular Medicine, 18, 2266-2274.
https://doi.org/10.1111/jcmm.12380
|
[35]
|
Green, E.M., Wakimoto, H., Anderson, R.L., et al. (2016) A Small-Molecule Inhibitor of Sarcomere Contractility Suppresses Hypertrophic Cardiomyopathy in Mice. Science, 351, 617-621. https://doi.org/10.1126/science.aad3456
|
[36]
|
熊萍, 符祖丰, 钟一鸣. 肥厚型心肌病预后因素的研究进展[J]. 赣南医学院学报, 2020, 40(9): 886-890.
https://doi.org/10.3969/j.issn.1001-5779.2020.09.005
|